Summary
Arginine and aspartic acid pharmacokinetics have been studied in rats following the simultaneous oral and intravenous administration of an aqueous solution containing 0.1 mmol of radiolabeled amino acids (U-[14C]-arginine and [3H-aspartic acid) per rat.
The assays of total free arginine and aspartic acid have been carried out using a spectrophotometric technique. Exogenous fractions of the two amino acids have been determined by the isotopic dilution method.
Pharmacokinetic parameters of the two amino acids were estimated assuming a two compartment mammillary open system.
A significant increase of blood levels of these two amino acids has been observed. This increase was less marked via the oral route (bioavailability of 0.49 for arginine and 0.24 for aspartic acid). One minute after intravenous administration, about 12 % of each amino acid were found in the free form in the plasma, and the half-life of arginine was almost twice that of aspartic acid. After oral administration the opposite was observed.
The plasma level of these two amino acids has been observed to increase after administration by either route 400 minutes after administration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Knopf R.F., Conn. J.W. and Fajans S.S. (1965): Plasma growth hormone response to intravenous administration of amino acids. J. Clin. Endocrinol. Metab.,25, 1140.
Mérimée T.J., Lillicrap D.A. and Rabinowitz D. (1965): Effect of arginine on serum-levels of human growth hormone. Lancet,2, 668–70.
Mérimée T.J., Rabinowitz D., Riggs L., Burgess J.A., Rimoin D.L. and Mc Kysick V.A. (1967): Plasma growth hormone after arginine infusion. N. Engl. J. Med.,276, 434–39.
Job J.C. (1972): Effets du chlorhydrate d’arginine sur la sécrétion d’hormone hypophysaire de croissance et sur la croissance des enfants. Rev. Pediatr.,3, 173–85.
Campistron G. (1980): Approche pharmacologique de l’arginine et de l’acide aspartique. Thèse de Sciences Pharmaceutiques (Etat), Toulouse.
Franchimont P., Luyckx A., Campistron G. and Cros J. (1979): Effets de l’aspartate d’arginine sur la sécrétion de somatotrophine, insuline et glucagon chez le rat. Thérapie,34, 641–45.
Gordin A., Meyers C, Arimura A., Coy D.H. and Schally A.V. (1977): An in vivo model for testing inhibition of arginine-induced insulin and glucagon release by somatostatin analogs. Acta Endocrinol.86, 833–41.
Franchimont P., Campistron G. and Cros J.: Effets de l’aspartate d’arginine et de ses constituants sur la sécrétion de somatotrophine, insuline et glucagon chez le rat. (In press)
Waeldele G. and Stoclet J.C. (1973): Cathétérisme permanent de l’aorte thoracique. J. Physiol. (Paris),66, 357–66.
Fabier J.C. (1976): Elimination en cours de la maladie de Paget d’un peptide glutamylhydroxyproline. Thèse de Spécialité de Sciences, Toulouse.
Gibaldi M. and Perrier D. (1975): Pharmacokinetics. Drugs and Pharmaceutical Sciences. Dekker, New-York, Basel.
Koch-Weser J. (1974): Bioavaibility of drugs (I). N. Engl. J. Med., 233–37.
Koch-Weser J. (1974): Bioavaibility of drugs (II). N. Engl. J. Med., 503–06.
Gruemer H.D., Koblet H. and Woodard C. (1961): Phenylalanine metabolism in phenylpyruvic condition. Part I-Distributions pools size and turnover rat in human phenyl ketonuria. J. Clin. Invest.,40, 1758–65.
Henriques O.B., Henriques S.B. and Neuberger A. (1955): Quantitative aspects of glycine metabolism in the rabbit. Biochem. J.,60, 409–24.
Nyhan W.L. and Childs B. (1964): Hyperglycinemia (V). The miscible pool and turnover rate of glycine and the formation of serine. J. Clin. Invest.,43, 2404–409.
Reilly P.E.B, and Green J.R. (1975): Multiexponential analysis of plasma free amino acid kinetics in the rat. Biochim. Biophys. Acta,381, 424–30.
Waterlow J.C. and Stephen J.M.L. (1967): The measurement of total lysine turnover in the rat by intravenous infusion of L-lysine U14C. Clin. Sci.,33, (3), 489–506.
Chami J., Reidenberg M.M., Wellner D., David D.S., Rubin A.L. and Stenzel K.H. (1978): Pharmacokinetics of essential amino acids in chronic dialysis patients. Am. J. Clin. Nutr.,31, 1652–59.
Jagenburg R., Olsson R., Regardh CG. and Rodjer S. (1977): Kinetics of intravenous administered L-phenyl-alanine in patients with cirrhosis of the liver. Clin. Chem. Acta,78, 453–63.
Campistron G., Fabre J., Guiraud R., Le Net R., Cros J. & Puget A. (1979): The measurement of circulation blood volume and of the blood volume impugnating organs in rat and rabbit using113m. In labelled trans-ferrin. Int. J. Nucl. Med. Biol.,6, (3), 167–68.
Blanquet P. and Laparra J. (1968): Localisation de l’ aspartate d’arginine dans l’organisme lors d’administrations répétées, Sem. Hôp. (Paris),44, 646–47.
Blanquet P. and Laparra J. (1968): Etude de la fixation et du métabolisme de l’aspartate d’arginine par la méthode de radioisotopes. Sem. Hôp. (Paris),44, 1161–63.
Perez G.O., Epstein M., Rietberg B. and Loutzenhiser R. (1978): Metabolism of arginine by the isolated perfused rat kidney. Am. J. Physiol.,235, 376–80.
Vidrich A., Airhart J., Bruno M.K. and Khairalla E.A. (1977): Compartmentation of free amino acids for protein biosynthesis. Biochem. J.,162, 257–66.
Harper H.A. (1949): Intravenous amino acid tolerance studies in humans. Proc. Soc. Exp. Biol. Med.,72, 184–87.
Fodor O., Szantay I., Tamas S.T. and Szabo P. (1969): Elimination of exogeneous aspartic acid metabolites related to the way of administration. Rev. Roumaine Bioch.,6, 189–95.
Kamin H. and Handler P. (1952): Effets of presence of other amino acids upon intestinal absorption of single amino acids in the rat. Am. J. Physiol.,169, 305–8.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Campistron, G., Guiraud, R., Cros, J. et al. Pharmacokinetics of arginine and aspartic acid administered simultaneously in the rat: I plasma kinetics. European Journal of Drug Metabolism and Pharmacokinetics 7, 307–313 (1982). https://doi.org/10.1007/BF03189634
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03189634